Visit the WHO website for the most current news and information about the coronavirus pandemic.
US pharmaceutical giant Pfizer announced it has a vaccine that showed 95% efficacy in tests conducted on 43,538 people in six countries, with no serious safety concerns. Moderna, an American biotech company, announced this week that its vaccine has been demonstratedand also relatively safe in a trial involving more than 30,000 people. Each vaccine requires a starting dose plus another “booster dose” a few weeks later.
Both companies plan to apply for an emergency permit from the FDA this month. Pfizer expects, if authorized, to produce up to 50 million doses of vaccines by 2020 and 1.3 billion by 2021. Moderna plans to ship 20 million doses by 2020 and another 500 million to 1 billion by 2021, if permitted. With more than 330 million people in the US alone,Immediately – the first doses to hit the market are likely to go to healthcare workers, followed by essential workers, those with underlying medical conditions, and older adults.
Pfizer and Moderna represent just the tip of the iceberg. Currently, there are 67 coronavirus vaccines in various stages of clinical trials, and a handful are almost ready to apply for authorization. Most experts think we’ll have a few more ready to distribute in early 2021, but life may not start to return to normal until 2022.
Here we walk you through the top news about coronavirus vaccines and explain where the most promising candidates stand. This article is regularly updated and is intended as a general overview and not a source of medical advice. If you are looking for more information about coronavirus testing,.
Important news about COVID-19 vaccines
The development of the COVID-19 vaccine has been rapid
There are currently several acceleration efforts underway, such as the White House’s Operation Warp Speed, which aims to cut the red tape to accelerate vaccine development and be ready to distribute vaccines once they get FDA approval. So far, the US government has pledged more than $ 10 billion to various vaccine manufacturers to obtain a total of 800 million doses of vaccine.
Vaccines typically take about 10 to 15 years to develop and approve, through four stages, including human trials. But with Operation Warp Speed, approved vaccine projects can send data to the FDA little by little, instead of submitting all of the data from a four-phase trial at once.
Meanwhile, the program also supports financial efforts to start manufacturing doses while clinical trials are ongoing. That means that if and when those vaccines are authorized, there will already be a supply of doses that can be distributed nationally.
Other promising coronavirus vaccines from UK, US and China
Here’s a quick look at some of the front runners alongside Pfizer and Moderna in the race to find a vaccine for COVID-19, including where the vaccines are developed, where they test them, and when scientists think they might be ready for widespread distribution, if known.
Oxford University / AstraZeneca (UK): AstraZeneca began testing on 100,000 human volunteers in at least three countries. Lead investigator Dr. Sarah Gilbert had initially said AstraZeneca is aiming for a fall 2020 release and while that may be optimistic on this point after briefly pausing the process to investigate a participant’s illness, it does not appear to have slowed down significantly .
Sinovac (China): Currently, the vaccine is being tested on about 10,000 human volunteers in China and about 9,000 in Brazil, and will soon begin testing on about 1,900 subjects in Indonesia. Honesti Basyir, the president of Bio Farma, Sinovac’s Indonesian partner, has said he expects the vaccine to be ready in early 2021.
Sinopharm (China): Currently, around 15,000 volunteers in the Middle East are being tested in a trial that the state-owned company expects to take three to six months. Initial results suggest the drug is safe and at least somewhat effective. Sinopharm recently built a second facility to produce the vaccine, doubling its capacity to approximately 200 million doses per year.
CanSino Biologics (China): CanSino’s vaccine, which will begin large-scale human trials this summer, has already been approved by the Chinese military. The vaccine is based on a modified cold virus, which some experts warn could make it less effective than other vaccination efforts.
How many vaccines does the US need?
We probably won’t know until next year, but Fauci has suggested that we might need different vaccines created and distributed by different labs to end the pandemic, in an article published May 11 in the journal Science has been published. He has also said he envisions that different vaccines will be given to different patient populations. For example, one vaccine for the elderly or other high-risk patients, another for healthy adults and another for children.
What if people don’t trust the vaccines?
Getting one or more vaccines through clinical trials to FDA approval is just the first part of the journey. The next thing is to convince people to take it. Sixty-three percent of U.S. adults expressed concerns about the safety of a coronavirus vaccine, according to an Oct. 19 Harris Poll, with 40% of respondents specifically concerned that the development is to fast. Some people are reported to be concerned about possible side effects.
Life in the US will return to normal if we achieve what scientists call “herd immunity,” which, with regard to the coronavirus, means that at least 60% to 70% of the population is immune. As long as enough people are taking the vaccine to reach that level, it doesn’t matter if a few people object or refuse to take the vaccine for other reasons, such as if they are not healthy enough to be vaccinated.
What to do until a coronavirus vaccine is approved?
Coronaviruses are a large class of viruses and so far there are none of these vaccines. While early results are promising, there is no guarantee that a vaccine will be ready by 2021. Statistically, only about 6% of vaccine candidates ever make it to the market, according to an April Reuters report. However, health officials are very optimistic that the Pfizer vaccine and similar vaccines can end the coronavirus pandemic.
Whether COVID-19 vaccines are effective in stopping the spread of coronavirus depends a lot on how our bodies build up immunity to the disease. Here’s what we know so far about whether or not you can. Testing is also key to slowing the spread of the coronavirus – learn more about a device that can yield results in . Finally, learn how all of these issues and more affect US President-elect Joseph .
The information in this article is for educational and informational purposes only and is not intended to be health or medical advice. Always consult a physician or other qualified health care practitioner if you have any questions about a medical condition or health goals.